Literature DB >> 23325441

Diagnosis of coeliac disease in children younger than 2 years.

Zrinjka Mišak1, Iva Hojsak, Oleg Jadrešin, Alemka Jaklin Kekez, Slaven Abdović, Sanja Kolaček.   

Abstract

BACKGROUND AND AIM: To diagnose coeliac disease (CD) in children younger than 2 years, the old ESPGHAN criteria based on 3 small bowel biopsies were recommended until recently. The aim of the present study was to investigate the applicability of only 1 small intestinal biopsy plus positive serology for the diagnosis of CD in children younger than 2 years.
METHODS: A prospective cohort study included 81 patients younger than 2 years with symptoms suggestive of CD, who all completed the diagnostic procedure based on 3 small bowel biopsies. According to the finding of the third biopsy, patients were divided into group A-CD confirmed (N = 44), and group B-CD not confirmed, after the gluten challenge (N = 37).
RESULTS: At the time of the first biopsy, total villous atrophy (Marsh IIIc) was found more often in group A than in group B (77% vs 27%, P < 0.01). Also, all of the studied antibodies were more frequently positive in group A than in group B (P < 0.01 for all of the tested antibodies). Positive anti-endomysial antibodies and Marsh IIIc finding were the best discriminators between the group A and the group B and considerably contributed to the prediction of CD.
CONCLUSIONS: The second and the third biopsies (before and after the gluten challenge) may also be avoided when diagnosing CD in children younger than 2 years provided that the child, at the time of presentation, has positive anti-endomysial antibodies and Marsh IIIc on the small bowel biopsy. A gluten challenge should be still considered in all other children younger than 2 years.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23325441     DOI: 10.1097/MPG.0b013e3182716861

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  6 in total

1.  Application of the Biopsy-Sparing ESPGHAN Guidelines for Celiac Disease Diagnosis in Adults: A Real-Life Study.

Authors:  Konstantinos Efthymakis; Mariaelena Serio; Angelo Milano; Francesco Laterza; Antonella Bonitatibus; Marta Di Nicola; Matteo Neri
Journal:  Dig Dis Sci       Date:  2017-07-17       Impact factor: 3.199

2.  Symptom positivity is essential for omitting biopsy in children with suspected celiac disease according to the new ESPGHAN guidelines.

Authors:  Jiri Nevoral; Radana Kotalova; Ondrej Hradsky; Vera Valtrova; Kristyna Zarubova; Jan Lastovicka; Eva Neubertova; Marketa Trnkova; Jiri Bronsky
Journal:  Eur J Pediatr       Date:  2013-11-15       Impact factor: 3.183

3.  Celiac disease in pediatric patients according to HLA genetic risk classes: a retrospective observational study.

Authors:  Carlo Tolone; Marisa Piccirillo; Pasquale Dolce; Salvatore Alfiero; Mattia Arenella; Marina Sarnataro; Patrizia Iardino; Alessia Pucciarelli; Caterina Strisciuglio
Journal:  Ital J Pediatr       Date:  2021-05-05       Impact factor: 2.638

4.  Influence of HLA on clinical and analytical features of pediatric celiac disease.

Authors:  Eva Martínez-Ojinaga; Marta Fernández-Prieto; Manuel Molina; Isabel Polanco; Elena Urcelay; Concepción Núñez
Journal:  BMC Gastroenterol       Date:  2019-06-13       Impact factor: 3.067

5.  Transition from childhood to adulthood in coeliac disease: the Prague consensus report.

Authors:  Jonas F Ludvigsson; Lars Agreus; Carolina Ciacci; Sheila E Crowe; Marilyn G Geller; Peter H R Green; Ivor Hill; A Pali Hungin; Sibylle Koletzko; Tunde Koltai; Knut E A Lundin; M Luisa Mearin; Joseph A Murray; Norelle Reilly; Marjorie M Walker; David S Sanders; Raanan Shamir; Riccardo Troncone; Steffen Husby
Journal:  Gut       Date:  2016-04-18       Impact factor: 23.059

Review 6.  The Spectrum of Differences between Childhood and Adulthood Celiac Disease.

Authors:  Rachele Ciccocioppo; Peter Kruzliak; Giuseppina C Cangemi; Miroslav Pohanka; Elena Betti; Eugenia Lauret; Luis Rodrigo
Journal:  Nutrients       Date:  2015-10-22       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.